GBM is characterized by rapid progression and treatment resistance, with a median overall survival (mOS) of 12–15 months and a 5-year survival rate below 10%, varying by prognostic factors such as age, functional status (Karnofsky Performance Status [KPS]), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, tumor location, and involvement of deep structures or functional areas [6,7,8,9]. The gene discussed is MGMT; the disease is glioblastoma.